3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Triple Negative Breast Neoplasms
2
Sarcoma
2
Recurrence
2
Neoplasms
2
Glioma
2
Wilms Tumor
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Temozolomide
6
Cyclophosphamide
5
Filgrastim
3
Automobiles
3
sargramostim
2
fludarabine
2
Thalidomide
2
Magnetic Resonance Spectroscopy
2
Etoposide
2
Carmustine
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
veliparib
1
trifluridine tipiracil drug combination
1
trametinib
1
thymoglobulin
1
temsirolimus
1
sonidegib
1
ribociclib
1
reolysin
1
pegfilgrastim
1
ibrutinib
1
fludarabine phosphate
1
entinostat
1
carboxyamido-triazole
1
azurin (50-77)
1
aldesleukin
1
Zoledronic Acid
1
Vincristine
1
Verteporfin
1
Valproic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neuroectodermal Tumors, Primitive
×
CLR1404
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled